Loading clinical trials...
Loading clinical trials...
A Phase I Study Evaluating the Safety, Tolerability, Biodistribution and Shedding of Oncolytic Vaccinia Virus GC001, Pharmacodynamics, Immunogenicity, and Antitumor Activity of the Virus in Patient With Recurrent or Progressive Gliomas
Conditions
Interventions
A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Recurrent or Progressive Gliomas of the Brain
Locations
1
China
Beijing Tiantan Hospital,Capital Medical University
Beijing, Beijing Municipality, China
Start Date
October 8, 2024
Primary Completion Date
February 8, 2026
Completion Date
August 8, 2026
Last Updated
March 13, 2025
NCT03904628
NCT00890786
li wenbin, Professor
CONTACT
Lead Sponsor
GONGCHU Biotechnology Co., Ltd
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions